IBSA
2.2.2024 14:33:26 CET | Business Wire | Press release
After a thorough overhaul in the shipyard to prepare the boat for the 2024 transoceanic races, the third season of the Class40 IBSA will start with two monumental tests, scheduled between April and July. As holder of first place in the international Class40 Circuit and the 24-hour Class40 distance record, both achieved during the 2023 season, Alberto Bona is getting ready to participate in the Transat CIC, to be held between April and May, and in the Transat Québec Saint-Malo, scheduled between June and July, to then complete the season with the Normandy Channel Race.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240202006265/en/
“We called it the season of courage”, stated Giorgio Pisani, Vice President IBSA Group and Leader of the project Sailing into the Future. Together. “But it will also be the season of maturity, for both Alberto and our project. In 2023 we achieved great sporting results, but also human ones, thanks to the commitment, consistency and resolution in completing the objectives we had set for ourselves. The 2024 season promises to be exciting: behind us, we have the experience that we strategically need to best manage the planned programme, while in our hearts is the courage to face any challenge, with the enthusiasm of the first day”.
“This third season with the Class40 IBSA”, commented Bona, “opens with a legendary regatta. I have enormous respect for this course, which I have never done; it’s a new challenge for me: a challenging route in the North Atlantic, in the first months of the season, very difficult due to wind, sea and current conditions. We are making some changes to the boat, in order to be best prepared for this first solo transoceanic. It’s important work”, continued Alberto, “which requires time and accurate assessments. On paper, it’s the most difficult regatta I have ever done. A beautiful adventure, also for IBSA, with a season that will take us to America and on less travelled routes; a season which I hope will be greatly satisfactory for everyone. I used to dream with the great navigators’ stories of the OSTAR, and I didn’t think that one day I would be able to do it myself... especially with a Class40!”.
The season will begin on April 28, with the Transat CIC, the new name of the oldest transoceanic regatta, the first edition of which took place in 1960. Then it was called the OSTAR; later it was renamed 1 Star and today is simply known as The Transat. Legendary names in ocean sailing have won it, from Sir Francis Chichester to Eric Tabarly. “This Transat is also the regatta in which the world discovered the great talent of Ellen MacArthur, who made her debut at just 23 years of age in this very difficult race”, recalled Bona. “It’s a solo regatta for which I have great expectations. I’m happy to go back to solo sailing after a season spent entirely with a crew. After the 2022 Route du Rhum, finding myself alone on the Class40 IBSA with so much more experience and knowledge of the boat is a great challenge”.
Anticipation is huge, after the 2020 edition was cancelled due to the pandemic: the regatta will therefore start again from the 15th edition, eight years after the previous one. The race will depart from Lorient, Brittany, on April 28 (the village will start celebrating on April 23), and arrive in New York, after over 3,000 miles of solo sailing. There will be a maximum of 80 boats at the start: 25 Class40s, 35 IMOCAs, 10 Ocean Fiftys and 10 vintage sailing boats, with registrations closing on January 31. The Class40 IBSA is automatically qualified, thanks to her participation in the 2022 Route du Rhum.
Sailing under the Statue of Liberty will certainly be a great thrill, as will be carrying the Class40 IBSA even further north, up to Canada, with an unforgettable 1,200 mile journey that will lead to the second, and equally legendary, challenge – the Transat Quebec Saint-Malo, one of the few Atlantic regattas sailed “in reverse”, from West to East, crossing the Northern waters and navigating for over 300 miles along a river, the St. Lawrence, in Canada. Now in its 10th edition – it also did not take place four years ago, due to COVID – and dedicated to the Ultim, Class40, IMOCA, Ocean Fifty and Mono and multihull categories between 45 and 65 feet, the Québec Saint-Malo is a regatta for a crew of three. Sailors will start on June 30 and – after dealing with the waters of the North Atlantic – will land in Saint-Malo, where three years ago everything began for the Class40 IBSA, with the departure for the Route du Rhum.
“After the Quebec Saint-Malo”, concluded Alberto, “we will be back in the La Trinité shipyard to get ready for the last event of the year, the Normandy Channel Race. These three regattas will, I hope, allow us to defend our Class40 championship title. It will be another challenging season for everyone, with thousands of miles behind and hopefully with more good results”.
THE PROJECT: The three-year project Sailing into the Future. Together was launched in January 2022. The partnership between IBSA and skipper Alberto Bona was born on common bases and values, and aims to use sailing as a corporate communication vehicle towards the market and the nautical world. Ingenuity, courage, innovation, responsibility are elements that unites IBSA and Alberto, and the oceanic challenge, in addition to the sporting competition, also metaphorically represents the company’s history, philosophy and vision, which are always oriented towards and are part of a path that brings IBSA increasingly closer to the topic of environmental and social sustainability, with a particular focus on inclusive sailing projects for people with disabilities. In November 2022, the Route du Rhum was the first sporting stage of the project Sailing into the Future. Together. In 2023, Bona and the Class40 IBSA participated in six regattas, including the Rolex Fastnet Race and the Transat Jacques Vabre. With two victories and three podiums, the record for the highest number of miles covered in 24 hours and over 15,000 miles sailed, Bona won first place overall in the Class40 International Championship. In 2024, between April and July, he will face two of the toughest transatlantic races on the international scene: the Transat CIC from Lorient (France) to New York and the Quebec Saint-Malo (from Canada to France). |
|
THE SKIPPER: Alberto Bona is from Turin, and has a degree in philosophy. As a university student, he won the Panerai trophy aboard Stormvogel, fast ULDB and historic boat with which he crossed the Atlantic Ocean for the first time, winning the ARC with a New Zealand crew. In 2012 he took part in the Minitransat, finishing 5th, one of the best Italian results ever in this category. In 2015, he switched to the prototype category Mini 6.50 with Promostudi La Spezia: he won the Italian championship and finished second in the ocean crossing Les Sables-Azores. In 2017 he discovered the Class40: on Giovanni Soldini’s former Telecom Italia, he participated in the Transat Jacques Vabre, where he was forced to withdraw when he was in sixth place. In 2019 he was aboard the Maserati Multi 70 trimaran, one of the world’s fastest boats, where he practiced on the foils before moving on to the Figaro Beneteau 3, aboard which he participated in the Solitaire; the only Italian registered, in 2020 he finished 7th among the rookies in the first year and 16th overall. In 2021 he won the Italian offshore team title and the Europeans in mixed doubles aboard the Figaro 3. In 2022 he started the new project in partnership with IBSA: after an eighth place in the Route du Rhum 2022, in 2023 Alberto won the Class40 International Championship, closing a season with three podiums and over 15,000 miles covered. |
|
THE BOAT: Designed by French naval architect Sam Manuard and built by the JPS Production shipyard, Alberto Bona’s boat is a Class40 Mach 5 model. Its main characteristics are: scow bow – rounded and with a wider and flatter shape than standard bows – designed to stay high above the water and avoid being submerged; all-round hull, particularly performing in conditions of strong tailwinds; and a large, shielded cockpit, to face extreme conditions of navigation in as comfortable and safe as possible positions. |
|
IBSA: IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 countries on 5 continents, through the Company’s 18 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 900 million CHF, and employs over 2,200 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility. |
For more information visit www.ibsasailing.com/en/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240202006265/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom